132 related articles for article (PubMed ID: 21414780)
1. Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
Fox BM; Natero R; Richard K; Connors R; Roveto PM; Beckmann H; Haller K; Golde J; Xiao SH; Kayser F
Bioorg Med Chem Lett; 2011 Apr; 21(8):2460-7. PubMed ID: 21414780
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
Mihalic JT; Fan P; Chen X; Chen X; Fu Y; Motani A; Liang L; Lindstrom M; Tang L; Chen JL; Jaen J; Dai K; Li L
Bioorg Med Chem Lett; 2012 Jun; 22(11):3781-5. PubMed ID: 22542010
[TBL] [Abstract][Full Text] [Related]
3. Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
Washburn WN; Manfredi M; Devasthale P; Zhao G; Ahmad S; Hernandez A; Robl JA; Wang W; Mignone J; Wang Z; Ngu K; Pelleymounter MA; Longhi D; Zhao R; Wang B; Huang N; Flynn N; Azzara AV; Barrish JC; Rohrbach K; Devenny JJ; Rooney S; Thomas M; Glick S; Godonis HE; Harvey SJ; Cullen MJ; Zhang H; Caporuscio C; Stetsko P; Grubb M; Maxwell BD; Yang H; Apedo A; Gemzik B; Janovitz EB; Huang C; Zhang L; Freeden C; Murphy BJ
J Med Chem; 2014 Sep; 57(18):7509-22. PubMed ID: 25165888
[TBL] [Abstract][Full Text] [Related]
4. Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
Kallander LS; Washburn DG; Hoang TH; Frazee JS; Stoy P; Johnson L; Lu Q; Hammond M; Barton LS; Patterson JR; Azzarano LM; Nagilla R; Madauss KP; Williams SP; Stewart EL; Duraiswami C; Grygielko ET; Xu X; Laping NJ; Bray JD; Thompson SK
Bioorg Med Chem Lett; 2010 Jan; 20(1):371-4. PubMed ID: 19926282
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
[TBL] [Abstract][Full Text] [Related]
6. Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.
Judd AS; Souers AJ; Kym PR
Curr Top Med Chem; 2008; 8(13):1152-7. PubMed ID: 18782010
[TBL] [Abstract][Full Text] [Related]
7. N-substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators.
Thewlis KM; Aldegheri L; Harries MH; Mookherjee C; Oliosi B; Ward SE
Bioorg Med Chem Lett; 2010 Dec; 20(23):7116-9. PubMed ID: 20971003
[TBL] [Abstract][Full Text] [Related]
8. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Högberg T; Frimurer TM; Sasmal PK
Bioorg Med Chem Lett; 2012 Oct; 22(19):6039-47. PubMed ID: 22954736
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.
Iyengar RR; Lynch JK; Mulhern MM; Judd AS; Freeman JC; Gao J; Souers AJ; Zhao G; Wodka D; Doug Falls H; Brodjian S; Dayton BD; Reilly RM; Swanson S; Su Z; Martin RL; Leitza ST; Houseman KA; Diaz G; Collins CA; Sham HL; Kym PR
Bioorg Med Chem Lett; 2007 Feb; 17(4):874-8. PubMed ID: 17234405
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
Kasai S; Kamata M; Masada S; Kunitomo J; Kamaura M; Okawa T; Takami K; Ogino H; Nakano Y; Ashina S; Watanabe K; Kaisho T; Imai YN; Ryu S; Nakayama M; Nagisa Y; Takekawa S; Kato K; Murata T; Suzuki N; Ishihara Y
J Med Chem; 2012 May; 55(9):4336-51. PubMed ID: 22490048
[TBL] [Abstract][Full Text] [Related]
11. Novel MCH1 receptor antagonists: a patent review.
Johansson A; Löfberg C
Expert Opin Ther Pat; 2015 Feb; 25(2):193-207. PubMed ID: 25522065
[TBL] [Abstract][Full Text] [Related]
12. Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: impacting hERG liability via aryl modifications.
McBriar MD; Guzik H; Shapiro S; Xu R; Paruchova J; Clader JW; O'neill K; Hawes B; Sorota S; Margulis M; Tucker K; Weston DJ; Cox K
Bioorg Med Chem Lett; 2006 Aug; 16(16):4262-5. PubMed ID: 16753297
[TBL] [Abstract][Full Text] [Related]
13. Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties.
Johansson A; Löfberg C; Antonsson M; von Unge S; Hayes MA; Judkins R; Ploj K; Benthem L; Lindén D; Brodin P; Wennerberg M; Fredenwall M; Li L; Persson J; Bergman R; Pettersen A; Gennemark P; Hogner A
J Med Chem; 2016 Mar; 59(6):2497-511. PubMed ID: 26741166
[TBL] [Abstract][Full Text] [Related]
14. Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.
Meyers KM; Kim N; Méndez-Andino JL; Hu XE; Mumin RN; Klopfenstein SR; Wos JA; Mitchell MC; Paris JL; Ackley DC; Holbert JK; Mittelstadt SW; Reizes O
Bioorg Med Chem Lett; 2007 Feb; 17(3):814-8. PubMed ID: 17107791
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2.
Vasudevan A; Wodka D; Verzal MK; Souers AJ; Gao J; Brodjian S; Fry D; Dayton B; Marsh KC; Hernandez LE; Ogiela CA; Collins CA; Kym PR
Bioorg Med Chem Lett; 2004 Oct; 14(19):4879-82. PubMed ID: 15341943
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of pyrrolidine derivatives as novel and potent sodium channel blockers for the treatment of ischemic stroke.
Seki M; Tsuruta O; Tatsumi R; Soejima A
Bioorg Med Chem Lett; 2013 Jul; 23(14):4230-4. PubMed ID: 23743284
[TBL] [Abstract][Full Text] [Related]
17. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Judd AS; Souers AJ; Wodka D; Zhao G; Mulhern MM; Iyengar RR; Gao J; Lynch JK; Freeman JC; Falls HD; Brodjian S; Dayton BD; Reilly RM; Gintant G; Limberis JT; Mikhail A; Leitza ST; Houseman KA; Diaz G; Bush EN; Shapiro R; Knourek-Segel V; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
Bioorg Med Chem Lett; 2007 Apr; 17(8):2365-71. PubMed ID: 17350253
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition.
Roth GJ; Heckel A; Kley JT; Lehmann T; Müller SG; Oost T; Rudolf K; Arndt K; Budzinski R; Lenter M; Lotz RR; Schindler M; Thomas L; Stenkamp D
Bioorg Med Chem Lett; 2015 Aug; 25(16):3270-4. PubMed ID: 26077492
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2.
Hudson S; Kiankarimi M; Rowbottom MW; Vickers TD; Wu D; Pontillo J; Ching B; Dwight W; Goodfellow VS; Schwarz D; Heise CE; Madan A; Wen J; Ban W; Wang H; Wade WS
Bioorg Med Chem Lett; 2006 Sep; 16(18):4922-30. PubMed ID: 16824755
[TBL] [Abstract][Full Text] [Related]
20. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
Meyers KM; Méndez-Andino JL; Colson AO; Warshakoon NC; Wos JA; Mitchell MC; Hodge KM; Howard JM; Ackley DC; Holbert JK; Mittelstadt SW; Dowty ME; Obringer CM; Reizes O; Hu XE
Bioorg Med Chem Lett; 2007 Feb; 17(3):819-22. PubMed ID: 17107796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
